Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Conference Coverage
The Association Between High Deductible Health Plans and Cancer Survival
07/02/2024
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented...
07/02/2024
Journal of Clinical Pathways
News
Analysis of the Impact Bruton Tyrosine Kinase Inhibitor Discontinuation Has After First- or Second-Line Therapy
08/22/2023

Emry Lloyd

Emry Lloyd
Researchers studied data on the outcomes of patients who received a BTKi in first or second line but subsequently discontinued treatment.
Researchers studied data on the outcomes of patients who received a BTKi in first or second line but subsequently discontinued treatment.
Researchers studied data on the...
08/22/2023
Journal of Clinical Pathways
Conference Coverage
Use of Pharmacogenomic Testing to Predict Bruton’s Tyrosine Kinase Inhibitor Treatment Intolerance
08/09/2023

Emry Lloyd

Emry Lloyd
Researchers conducted a study to determine whether cytochrome P450 polymorphisms can contribute to treatment intolerance in patients receiving Bruton’s tyrosine kinase inhibitors.
Researchers conducted a study to determine whether cytochrome P450 polymorphisms can contribute to treatment intolerance in patients receiving Bruton’s tyrosine kinase inhibitors.
Researchers conducted a study to...
08/09/2023
Journal of Clinical Pathways
Smita Agrawal, PhD.
Videos
Enhancing Line of Therapy Derivation Using Real-World Data From Electronic Health Records Via Integration of Medical Claims Data
08/08/2023

Featuring Smita Agrawal, PhD

Featuring Smita Agrawal, PhD
Smita Agrawal, PhD, executive director at ConcertAI, spoke about her study on deriving lines of therapy by integrating data from multiple data sources to improve accuracy.
Smita Agrawal, PhD, executive director at ConcertAI, spoke about her study on deriving lines of therapy by integrating data from multiple data sources to improve accuracy.
Smita Agrawal, PhD, executive...
08/08/2023
Journal of Clinical Pathways
News
The Impact of Demographic Factors on Time to Diagnosis for Patients With Diffuse Large B-Cell Lymphoma
08/03/2023

Grace Taylor

Grace Taylor
Researchers investigated how socioeconomic status, race, and primary language spoken at home can affect time to diagnosis for patients with diffuse large B-cell lymphoma (DLBCL).
Researchers investigated how socioeconomic status, race, and primary language spoken at home can affect time to diagnosis for patients with diffuse large B-cell lymphoma (DLBCL).
Researchers investigated how...
08/03/2023
Journal of Clinical Pathways
Puneeth Indurlal, MD
Videos
Impact of Dose Rounding Bevacizumab and its Biosimilars on Total Cost of Care for OCM Participants
07/26/2023

Featuring Puneeth Indurlal, MD

Featuring Puneeth Indurlal, MD ...
Puneeth Indurlal, MD, discusses the impact of dose rounding that targets bevacizumab and its biosimilars on the total cost of care and drug waste expenditures for Oncology Care Model participants in the US Oncology Network.
Puneeth Indurlal, MD, discusses the impact of dose rounding that targets bevacizumab and its biosimilars on the total cost of care and drug waste expenditures for Oncology Care Model participants in the US Oncology Network.
Puneeth Indurlal, MD, discusses...
07/26/2023
Journal of Clinical Pathways
Monica Schmidt, PhD.
Videos
The Impact of Elsevier ClinicalPath Oncology Treatment Pathways on Survival and Cost of Care
07/24/2023

Featuring Monica Schmidt, PhD

Featuring Monica Schmidt, PhD
In an interview with the Journal of Clinical Pathways, Monica Schmidt, PhD, MPH, discusses her study on the impact of using Elsevier’s ClinicalPath oncology pathways on short-term survival and cost of care from the patient and health system...
In an interview with the Journal of Clinical Pathways, Monica Schmidt, PhD, MPH, discusses her study on the impact of using Elsevier’s ClinicalPath oncology pathways on short-term survival and cost of care from the patient and health system...
In an interview with the Journal...
07/24/2023
Journal of Clinical Pathways
Aaron P. Mitchell, MD, MPH
Videos
Study Examines the Association Between Oncologists’ Receipt of Pharmaceutical Industry Payments and Use of Nonrecommended/Low-Value Treatments
07/20/2023

Featuring Aaron P. Mitchell, MD

Featuring Aaron P. Mitchell, MD ...
Aaron P. Mitchell, MD, MPH, discusses his research on the association of pharmaceutical industry payments to oncologists and their increased use of nonrecommended and/or low-value treatment methods.
Aaron P. Mitchell, MD, MPH, discusses his research on the association of pharmaceutical industry payments to oncologists and their increased use of nonrecommended and/or low-value treatment methods.
Aaron P. Mitchell, MD, MPH,...
07/20/2023
Journal of Clinical Pathways
Manali Kamdar Headshot
Videos
Overview of Treatment Options for Patients With Primary Refractory/Early Relapse Diffuse Large B-Cell Lymphoma
07/19/2023

Featuring Manali Kamdar, MD

Featuring Manali Kamdar, MD
Manali Kamdar, MD, University of Colorado Cancer Center, discusses the latest therapeutic options available for patients with primary refractory/early relapse diffuse large B-cell lymphoma.
Manali Kamdar, MD, University of Colorado Cancer Center, discusses the latest therapeutic options available for patients with primary refractory/early relapse diffuse large B-cell lymphoma.
Manali Kamdar, MD, University of...
07/19/2023
Journal of Clinical Pathways
Conference Coverage
Study Evaluates Sociodemographic Factors and Survival Outcomes for Patients with CLL/SLL
07/18/2023

Emry Lloyd

Emry Lloyd
Researchers analyzed whether sociodemographic characteristics influence the overall survival rate of Hispanic vs non-Hispanic patients with CLL/SLL
Researchers analyzed whether sociodemographic characteristics influence the overall survival rate of Hispanic vs non-Hispanic patients with CLL/SLL
Researchers analyzed whether...
07/18/2023
Journal of Clinical Pathways
Dr Danielle Gentile.
Videos
Comparison of Diversity Across Real-World Evidence, Randomized Clinical Trial, and SEER Data in Patients With Metastatic Breast Cancer
07/12/2023

Featuring Danielle Gentile, PhD

Featuring Danielle Gentile, PhD ...
Danielle Gentile, PhD, a senior scientist on Cardinal Health’s real-world evidence and insights team, discusses her research comparing diversity in real-world evidence, RCTs, and SEER data in patients with metastatic breast cancer.
Danielle Gentile, PhD, a senior scientist on Cardinal Health’s real-world evidence and insights team, discusses her research comparing diversity in real-world evidence, RCTs, and SEER data in patients with metastatic breast cancer.
Danielle Gentile, PhD, a senior...
07/12/2023
Journal of Clinical Pathways
Thomas Stricker, MD.
Videos
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer
07/12/2023

Featuring Thomas Stricker, MD

Featuring Thomas Stricker, MD
Thomas Stricker, MD, PhD, speaks with the Journal of Clinical Pathways about his research on the clinical impact of the timing of first line targeted therapy in aNSCLC patients with actionable driver oncogenes.
Thomas Stricker, MD, PhD, speaks with the Journal of Clinical Pathways about his research on the clinical impact of the timing of first line targeted therapy in aNSCLC patients with actionable driver oncogenes.
Thomas Stricker, MD, PhD, speaks...
07/12/2023
Journal of Clinical Pathways
Conference Coverage
Study Compares the Efficacy and Safety of Acalabrutinib vs Zanubrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia
07/07/2023

Emry Lloyd

Emry Lloyd
Researchers conducted a study to compare two drugs for R/R CLL treatment safety: acalabrutinib and zanubrutinib.
Researchers conducted a study to compare two drugs for R/R CLL treatment safety: acalabrutinib and zanubrutinib.
Researchers conducted a study to...
07/07/2023
Journal of Clinical Pathways
News
Analysis of Racial Disparities in Cancer-Specific Survival Rates of Patients with Diffuse Large B-Cell Lymphoma
07/06/2023

Grace Taylor

Grace Taylor
In a recent study, Soyon Lee, MPH, and John D. Seeger, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, examined the association between race and cancer-specific survival among patients with diffuse large B-cell lymphoma.
In a recent study, Soyon Lee, MPH, and John D. Seeger, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, examined the association between race and cancer-specific survival among patients with diffuse large B-cell lymphoma.
In a recent study, Soyon Lee,...
07/06/2023
Journal of Clinical Pathways
Janet Espirito, PharmD.
Videos
Real-World Response Endpoints in Patients With mNSCLC Treated With Chemotherapy Across Real-World Datasets
07/03/2023

Featuring Janet Espirito, PharmD

Featuring Janet Espirito, PharmD ...
Janet L. Espirito, PharmD, Senior Medical Director for Ontada, speaks with the Journal of Clinical Pathways about the significance of her research on real-world response endpoints in patients with mNSCLC treated with chemotherapy across...
Janet L. Espirito, PharmD, Senior Medical Director for Ontada, speaks with the Journal of Clinical Pathways about the significance of her research on real-world response endpoints in patients with mNSCLC treated with chemotherapy across...
Janet L. Espirito, PharmD,...
07/03/2023
Journal of Clinical Pathways
Theresa Dreyer, MPH
Videos
Perspective on Lessons Learned from Academic Practices Participating in OCM
06/30/2023

Featuring Theresa Dreyer, MPH

Featuring Theresa Dreyer, MPH
Theresa Dreyer, MPH, value-based care team lead for the Association of American Medical Colleges (AAMC), shares further insights from her ASCO 2023 presentation and discusses the benefits and challenges for academic practices participating in...
Theresa Dreyer, MPH, value-based care team lead for the Association of American Medical Colleges (AAMC), shares further insights from her ASCO 2023 presentation and discusses the benefits and challenges for academic practices participating in...
Theresa Dreyer, MPH, value-based...
06/30/2023
Journal of Clinical Pathways
Conference Coverage
Overall Survival Analysis of Patients with R/R LBCL Receiving Axicabtagene Ciloleucel vs Standard of Care Therapy: ZUMA-7 Study
06/27/2023

Grace Taylor

Grace Taylor
Jason Westin, MD, and colleagues examined the overall survival of patients with R/R LBCL who received axicabtagene ciloleucel vs standard of care for second-line therapy as part of the ZUMA-7 clinical trial.
Jason Westin, MD, and colleagues examined the overall survival of patients with R/R LBCL who received axicabtagene ciloleucel vs standard of care for second-line therapy as part of the ZUMA-7 clinical trial.
Jason Westin, MD, and colleagues...
06/27/2023
Journal of Clinical Pathways
Patricia Santos, MD
Videos
Health Care Access and Affordability for Adult Immigrant Cancer Survivors
06/26/2023

Featuring Patricia Santos, MD

Featuring Patricia Santos, MD
Patricia Santos, MD, Memorial Sloan Kettering Cancer Center, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about her research on the coverage and affordability of health care access for adult immigrant cancer...
Patricia Santos, MD, Memorial Sloan Kettering Cancer Center, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about her research on the coverage and affordability of health care access for adult immigrant cancer...
Patricia Santos, MD, Memorial...
06/26/2023
Journal of Clinical Pathways
Adam Kittai, MD
Videos
A Real-World Analysis of Factors Leading to Racial Disparities in the Overall Survival of Patients with CLL
06/22/2023

Featuring Adam Kittai, MD

Featuring Adam Kittai, MD
Adam Kittai, MD, The Ohio State University Comprehensive Cancer Center, discusses his study on the causes of racial disparities in the overall survival of patients with chronic lymphocytic leukemia.
Adam Kittai, MD, The Ohio State University Comprehensive Cancer Center, discusses his study on the causes of racial disparities in the overall survival of patients with chronic lymphocytic leukemia.
Adam Kittai, MD, The Ohio State...
06/22/2023
Journal of Clinical Pathways
Conference Coverage
Evaluation of a Medication Acquisition Program for Patient Access to Off-Label Treatment
06/21/2023

Emry Lloyd

Emry Lloyd
Researchers analyzed the success of their institution’s medication acquisition program for patients with cancer, including tracking clinical benefit.
Researchers analyzed the success of their institution’s medication acquisition program for patients with cancer, including tracking clinical benefit.
Researchers analyzed the success...
06/21/2023
Journal of Clinical Pathways
Dr Barb Kunz.
Videos
The Impact of Social Determinants of Health on Use of Germline Genetic Testing for Triple-Negative Breast Cancer
06/20/2023

Featuring Barb Kunz

Featuring Barb Kunz
Barb Kunz, the US Oncology Network, discusses her study on the impact of social determinants of health on use of germline genetic testing for triple-negative breast cancer in the community oncology setting.
Barb Kunz, the US Oncology Network, discusses her study on the impact of social determinants of health on use of germline genetic testing for triple-negative breast cancer in the community oncology setting.
Barb Kunz, the US Oncology...
06/20/2023
Journal of Clinical Pathways
Conference Coverage
Study Examines Real-World Outcomes of Novel Treatments for Diffuse Large B-Cell Lymphoma
06/14/2023

Emry Lloyd

Emry Lloyd
Researchers conducted a retrospective analysis to evaluate the outcomes of patients with R/R DLBCL treated with novel therapies, with a subanalysis of patients who received CAR T prior to novel therapies.
Researchers conducted a retrospective analysis to evaluate the outcomes of patients with R/R DLBCL treated with novel therapies, with a subanalysis of patients who received CAR T prior to novel therapies.
Researchers conducted a...
06/14/2023
Journal of Clinical Pathways
Lalan Wilfong, MD.
Conference Coverage
Benefits and Challenges of the Enhancing Oncology Model
06/13/2023
At the ASCO 2023 Annual Meeting, Lalan Wilfong, MD, provided an overview of the Enhancing Oncology Model and how it differs from and improves upon the Oncology Care Model.
At the ASCO 2023 Annual Meeting, Lalan Wilfong, MD, provided an overview of the Enhancing Oncology Model and how it differs from and improves upon the Oncology Care Model.
At the ASCO 2023 Annual Meeting,...
06/13/2023
Journal of Clinical Pathways
Conference Coverage
Real-World Outcomes by Race in Patients with Chronic Lymphocytic Leukemia in the informCLL Registry Study
06/12/2023

Grace Taylor

Grace Taylor
Data from the informCLL clinical trial, presented at the 2023 ASCO Annual Meeting, analyzed the impact of access to novel therapies on clinical outcomes stratified by race in patients with CLL/SLL.
Data from the informCLL clinical trial, presented at the 2023 ASCO Annual Meeting, analyzed the impact of access to novel therapies on clinical outcomes stratified by race in patients with CLL/SLL.
Data from the informCLL clinical...
06/12/2023
Journal of Clinical Pathways
Barragan-Carrillo, MD
Conference Coverage
Impact of Race and Payor Status on Nephrectomy Procedure Type in Patients With Renal Cell Carcinoma
06/08/2023
In an interview with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting, Regina Barragán-Carrillo, MD, discusses her study on the influence of race and payor status on the treatment patterns of partial versus radical nephrectomy...
In an interview with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting, Regina Barragán-Carrillo, MD, discusses her study on the influence of race and payor status on the treatment patterns of partial versus radical nephrectomy...
In an interview with the Journal...
06/08/2023
Journal of Clinical Pathways
Gregory Vidal, MD, Phd
Conference Coverage
Inequities in Next-Generation Sequencing Testing Among Patients With Advanced Non–Small Cell Lung Cancer
06/07/2023
Dr Gregory Vidal, Breast Medical Oncologist, West Cancer Center, Germantown, TN, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about his study on inequities in next-generation sequencing testing by race/ethnicity...
Dr Gregory Vidal, Breast Medical Oncologist, West Cancer Center, Germantown, TN, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about his study on inequities in next-generation sequencing testing by race/ethnicity...
Dr Gregory Vidal, Breast Medical...
06/07/2023
Journal of Clinical Pathways
Conference Coverage
Analysis Finds That Commuting Distance Affects Equitable Access to and Enrollment in US Cancer Clinical Trials
06/05/2023

Emry Lloyd

Emry Lloyd
In an abstract presented at ASCO 2023, researchers found that one-way commuting distance to US-based cancer trial sites is a key barrier to socioeconomically equitable clinical trial enrollment.
In an abstract presented at ASCO 2023, researchers found that one-way commuting distance to US-based cancer trial sites is a key barrier to socioeconomically equitable clinical trial enrollment.
In an abstract presented at ASCO...
06/05/2023
Journal of Clinical Pathways
Debra Patt, MD, PhD, MBA, Texas Oncology, US Oncology Network
Videos
Trastuzumab Deruxtecan Improves Survival vs Standard of Care for HER2-Low Metastatic Breast Cancer
07/06/2022
Debra Patt, MD, PhD, MBA, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with...
Debra Patt, MD, PhD, MBA, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with...
Debra Patt, MD, PhD, MBA,...
07/06/2022
Journal of Clinical Pathways
Conference Coverage
Efficacy of Virtual Live Education on the Knowledge of Gynecologists Caring for Patients With Ovarian Cancer
06/22/2022
Vanessa Carranza, PharmD, created an educational initiative that focused on obstetricians, gynecologists, and other health care professionals, aiming to evaluate their knowledge on PARP inhibitors in ovarian cancer, ability to identify those...
Vanessa Carranza, PharmD, created an educational initiative that focused on obstetricians, gynecologists, and other health care professionals, aiming to evaluate their knowledge on PARP inhibitors in ovarian cancer, ability to identify those...
Vanessa Carranza, PharmD,...
06/22/2022
Journal of Clinical Pathways
Mengyang Di, MD, PhD
Videos
Real-World Effectiveness of Rituximab Maintenance Among Older Patients With Mantle Cell Lymphoma
06/15/2022
Mengyang Di, MD, PhD, evaluates real-world treatment patterns and assesses the efficacy of rituximab maintenance following standard chemoimmunotherapy among older patients with MCL.
Mengyang Di, MD, PhD, evaluates real-world treatment patterns and assesses the efficacy of rituximab maintenance following standard chemoimmunotherapy among older patients with MCL.
Mengyang Di, MD, PhD, evaluates...
06/15/2022
Journal of Clinical Pathways
Conference Coverage
Impact of Biosimilar Substitution on Provider Risk in Value-Based Oncology Payment Models
06/14/2022

Ellen Kurek

Ellen Kurek
Researchers at the 2022 ASCO Annual Meeting estimated the impact of biosimilar substitution on financial risk to providers in oncology value-based payments by applying simulation approaches to model the episode framing, pricing, and risk...
Researchers at the 2022 ASCO Annual Meeting estimated the impact of biosimilar substitution on financial risk to providers in oncology value-based payments by applying simulation approaches to model the episode framing, pricing, and risk...
Researchers at the 2022 ASCO...
06/14/2022
Journal of Clinical Pathways
Conference Coverage
Examining the Prevalence of Prior Authorizations for Use of PARP Inhibitors in Ovarian Cancer
06/14/2022

Ellen Kurek

Ellen Kurek
Researchers at the 2022 ASCO Annual Meeting examined the prevalence of prior authorization for PARP inhibitors among patients with ovarian cancer overall, by frontline or recurrent maintenance, and by genetic status.
Researchers at the 2022 ASCO Annual Meeting examined the prevalence of prior authorization for PARP inhibitors among patients with ovarian cancer overall, by frontline or recurrent maintenance, and by genetic status.
Researchers at the 2022 ASCO...
06/14/2022
Journal of Clinical Pathways
Conference Coverage
Exploring Real-World Data on the Efficacy and Safety of Oncology Drugs
06/14/2022

Ellen Kurek

Ellen Kurek
A study presented at the ASCO Annual Meeting aimed to establish a data collection framework of EMR-based real-world data to evaluate the effectiveness and safety of cancer drugs.
A study presented at the ASCO Annual Meeting aimed to establish a data collection framework of EMR-based real-world data to evaluate the effectiveness and safety of cancer drugs.
A study presented at the ASCO...
06/14/2022
Journal of Clinical Pathways
Conference Coverage
Use of Homologous Recombination Thresholds for Forecasting Response to Platinum-Based Treatment in Triple-Negative Breast Cancer
06/14/2022

Ellen Kurek

Ellen Kurek
Researchers at ASCO conducted an exploratory analysis evaluating the ability of GIS thresholds of 33 or greater, and 42 or greater to predict response to platinum-based treatment in patients with triple-negative breast cancer.
Researchers at ASCO conducted an exploratory analysis evaluating the ability of GIS thresholds of 33 or greater, and 42 or greater to predict response to platinum-based treatment in patients with triple-negative breast cancer.
Researchers at ASCO conducted an...
06/14/2022
Journal of Clinical Pathways
Mazie Tsang, MD, MS
Videos
Referral Patterns and Health Care Utilization Among Patients With Hematologic Malignancies
06/14/2022
Mazie Tsang, MD, MS, discusses a study that evaluated referral patterns and health care utilization among patients with hematologic malignancies who were seen in an embedded outpatient palliative care clinic.
Mazie Tsang, MD, MS, discusses a study that evaluated referral patterns and health care utilization among patients with hematologic malignancies who were seen in an embedded outpatient palliative care clinic.
Mazie Tsang, MD, MS, discusses a...
06/14/2022
Journal of Clinical Pathways
Stephen Ansell, MD, PhD
Interview
First-Line Brentuximab Vedotin Plus Chemotherapy Improves OS in Classical Hodgkin Lymphoma
06/14/2022
Stephen Ansell, MD, PhD, discusses results from the ECHELON-1 trial, which found that brentuximab vedotin, doxorubicin, vinblastine, plus dacarbazine treatment resulted in a statistically significant reduction in the risk of death when...
Stephen Ansell, MD, PhD, discusses results from the ECHELON-1 trial, which found that brentuximab vedotin, doxorubicin, vinblastine, plus dacarbazine treatment resulted in a statistically significant reduction in the risk of death when...
Stephen Ansell, MD, PhD,...
06/14/2022
Journal of Clinical Pathways
Bijal Shah, MD
Videos
Real-World Treatment Patterns of Bruton Tyrosine Kinase Inhibitors Among Patients With Mantle Cell Lymphoma
06/14/2022
Bijal Shah, MD, discusses his study which assessed patient characteristics, treatment patterns and associated outcomes in real-world BTKi-treated patients with MCL.
Bijal Shah, MD, discusses his study which assessed patient characteristics, treatment patterns and associated outcomes in real-world BTKi-treated patients with MCL.
Bijal Shah, MD, discusses his...
06/14/2022
Journal of Clinical Pathways
Eloise Chapman-Davis, MD
Videos
Identifying Disparities in Genetic Testing Among Patients With Ovarian Cancer
06/14/2022
Eloise Chapman-Davis, MD, discusses her research on existing disparities in genetic counseling in ovarian cancer, finding that less than half of patients with newly diagnosed breast or ovarian cancer receive germline testing, despite NCCN...
Eloise Chapman-Davis, MD, discusses her research on existing disparities in genetic counseling in ovarian cancer, finding that less than half of patients with newly diagnosed breast or ovarian cancer receive germline testing, despite NCCN...
Eloise Chapman-Davis, MD,...
06/14/2022
Journal of Clinical Pathways
Conference Coverage
BRCA Variants in Patients With Ovarian Cancer and the Risk of Adverse Reactions
06/10/2022

Marta Rybczynski

Marta Rybczynski
A real-world study presented at the 2022 ASCO Annual Meeting found that BRCA variants may not increase the risk of adverse reactions among patients with ovarian cancer.
A real-world study presented at the 2022 ASCO Annual Meeting found that BRCA variants may not increase the risk of adverse reactions among patients with ovarian cancer.
A real-world study presented at...
06/10/2022
Journal of Clinical Pathways
Conference Coverage
Treatment Patterns and Efficacy of Bruton Tyrosine Kinase Inhibitors in Patients With MCL
06/09/2022

Robert Fee

Robert Fee
Retrospective multicenter chart review conducted in the Cardinal Health Oncology Provider Extended Network assessed treatment patterns and associated outcomes in patients with MCL who were treated with BTKi.
Retrospective multicenter chart review conducted in the Cardinal Health Oncology Provider Extended Network assessed treatment patterns and associated outcomes in patients with MCL who were treated with BTKi.
Retrospective multicenter chart...
06/09/2022
Journal of Clinical Pathways
Conference Coverage
Bringing the Benefits of At-home Programs to Patients With Cancer Who Live in Rural Areas
06/09/2022

Robert Fee

Robert Fee
Researchers show how patients with cancer who are living in rural communities can receive the benefits of oncology hospital at home programs in a case study from the 2022 ASCO Annual Meeting.
Researchers show how patients with cancer who are living in rural communities can receive the benefits of oncology hospital at home programs in a case study from the 2022 ASCO Annual Meeting.
Researchers show how patients...
06/09/2022
Journal of Clinical Pathways
Conference Coverage
Study Examines Charges Associated With US Hospital Payer-Specific Negotiated Mammography
06/09/2022

Robert Fee

Robert Fee
A cross-sectional study of US acute care and critical access hospitals presented at the 2022 ASCO Annual Meeting examined the factors associated with payer-negotiated mammography charges.
A cross-sectional study of US acute care and critical access hospitals presented at the 2022 ASCO Annual Meeting examined the factors associated with payer-negotiated mammography charges.
A cross-sectional study of US...
06/09/2022
Journal of Clinical Pathways
Conference Coverage
Case Study Assesses Self-Reported Financial Difficulties Among Patients With Multiple Myeloma or Chronic Lymphocytic Leukemia
06/09/2022

Robert Fee

Robert Fee
A study presented by the Alliance for Clinical Trials in Oncology at the 2022 ASCO Annual Meeting confirms that many patients with blood cancers experience financial difficulties.
A study presented by the Alliance for Clinical Trials in Oncology at the 2022 ASCO Annual Meeting confirms that many patients with blood cancers experience financial difficulties.
A study presented by the...
06/09/2022
Journal of Clinical Pathways
Conference Coverage
Factors Predicting the Likelihood of Undergoing Biomarker Testing in Ovarian Cancer
06/08/2022

Marta Rybczynski

Marta Rybczynski
According to findings presented at ASCO 2022, only 55% of patients with ovarian cancer underwent biomarker testing due to factors such as insurance type, ECOG status, and region.
According to findings presented at ASCO 2022, only 55% of patients with ovarian cancer underwent biomarker testing due to factors such as insurance type, ECOG status, and region.
According to findings presented...
06/08/2022
Journal of Clinical Pathways
Conference Coverage
Apatinib Safe, Effective for the Treatment of Advanced Platinum-Resistant Recurrent Epithelial Ovarian Cancer
06/08/2022

Marta Rybczynski

Marta Rybczynski
Apatinib therapy may be effective among patients with advanced platinum-resistant relapsed epithelial ovarian cancer, with manageable toxicities, according to a study presented at ASCO 2022.
Apatinib therapy may be effective among patients with advanced platinum-resistant relapsed epithelial ovarian cancer, with manageable toxicities, according to a study presented at ASCO 2022.
Apatinib therapy may be...
06/08/2022
Journal of Clinical Pathways
Conference Coverage
Understanding Oncologists’ Attitudes on Communicating With Patients About the Cost of Cancer
06/08/2022

Amber Denham

Amber Denham
According to data from an online survey summarized at the 2022 ASCO Annual Meeting, despite believing cost of cancer care should be discussed in the clinic, most hematologists/oncologists surveyed did not do so.
According to data from an online survey summarized at the 2022 ASCO Annual Meeting, despite believing cost of cancer care should be discussed in the clinic, most hematologists/oncologists surveyed did not do so.
According to data from an online...
06/08/2022
Journal of Clinical Pathways
Conference Coverage
Real-world Treatment Patterns for Patients With Metastatic Castration-Resistant Prostate Cancer
06/06/2022

Robert Fee

Robert Fee
Although numerous treatments with different mechanisms of action are approved for metastatic castration-resistant prostate cancer (mCRPC), the sequencing for management of these patients has been evolving post availability of trials.
Although numerous treatments with different mechanisms of action are approved for metastatic castration-resistant prostate cancer (mCRPC), the sequencing for management of these patients has been evolving post availability of trials.
Although numerous treatments...
06/06/2022
Journal of Clinical Pathways
Conference Coverage
The Financial Impact of Biosimilar Adoption in the Oncology Care Model
06/05/2022

Robert Fee

Robert Fee
In a study presented at the 2022 ASCO Annual Meeting, researchers examined the utilization and the financial impact of biosimilar adoption in The US Oncology Network Over a six-month period.
In a study presented at the 2022 ASCO Annual Meeting, researchers examined the utilization and the financial impact of biosimilar adoption in The US Oncology Network Over a six-month period.
In a study presented at the 2022...
06/05/2022
Journal of Clinical Pathways
Conference Coverage
Real-World Survival Outcomes With PARP Inhibitor Maintenance in Advanced Ovarian Cancer
06/05/2022

Robert Fee

Robert Fee
Study examines patient records over five years to determine real-world efficacy benefits of PARPi therapy vs active surveillance confirms the efficacy benefits that have been demonstrated in randomized clinical trials of PARPis vs placebo.
Study examines patient records over five years to determine real-world efficacy benefits of PARPi therapy vs active surveillance confirms the efficacy benefits that have been demonstrated in randomized clinical trials of PARPis vs placebo.
Study examines patient records...
06/05/2022
Journal of Clinical Pathways
Conference Coverage
Bevacizumab-awwb Safe, Effective Among Patients With Metastatic Colorectal Cancer
06/04/2022

Robert Fee

Robert Fee
Study examines real-world effectiveness and safety of Bevacizumab-awwb, the first FDA-approved biosimilar to Avastin, among patients with metastatic colorectal cancer.
Study examines real-world effectiveness and safety of Bevacizumab-awwb, the first FDA-approved biosimilar to Avastin, among patients with metastatic colorectal cancer.
Study examines real-world...
06/04/2022
Journal of Clinical Pathways
Conference Coverage
Clinical Implications of Tumor-Based Next-generation Sequencing in Ovarian Cancer
06/04/2022

Robert Fee

Robert Fee
A study presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting assessed the clinical relevance of tumor-based next-generation sequencing (tbNGS) in a large cohort of patients with high-grade epithelial ovarian...
A study presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting assessed the clinical relevance of tumor-based next-generation sequencing (tbNGS) in a large cohort of patients with high-grade epithelial ovarian...
A study presented at the 2022...
06/04/2022
Journal of Clinical Pathways
Conference Coverage
Real-World Utilization and Comparative Effectiveness of Treatment Options for Cancer–Associated Venous Thromboembolism
06/04/2022

Janelle Bradley

Janelle Bradley
In the real-world setting, patients with cancer–associated venous thromboembolism remain on anticoagulation for a short period of time and DOACs and warfarin may be associated with better compliance than low molecular weight heparin.
In the real-world setting, patients with cancer–associated venous thromboembolism remain on anticoagulation for a short period of time and DOACs and warfarin may be associated with better compliance than low molecular weight heparin.
In the real-world setting,...
06/04/2022
Journal of Clinical Pathways
Conference Coverage
Pharmacist Interventions in Oral Oncolytics Program Shown to Provide Cost Savings
06/04/2022

Robert Fee

Robert Fee
A study presented at the 2022 ASCO Annual Meeting shows that pharmacist interventions in the Pharmacist-Managed Oral Chemotherapy Clinic at Kaiser Permanente San Diego led to significant overall cost savings to the health care system.
A study presented at the 2022 ASCO Annual Meeting shows that pharmacist interventions in the Pharmacist-Managed Oral Chemotherapy Clinic at Kaiser Permanente San Diego led to significant overall cost savings to the health care system.
A study presented at the 2022...
06/04/2022
Journal of Clinical Pathways
Conference Coverage
Bendamustine Plus Rituximab Among Older Patients With Newly Diagnosed Mantle Cell Lymphoma
06/04/2022

Robert Fee

Robert Fee
Research presented at ASCO demonstrates that ibrutinib, when combined with bendamustine-rituximab, improved progression-free survival by 50% for older patients with newly diagnosed mantle cell lymphoma.
Research presented at ASCO demonstrates that ibrutinib, when combined with bendamustine-rituximab, improved progression-free survival by 50% for older patients with newly diagnosed mantle cell lymphoma.
Research presented at ASCO...
06/04/2022
Journal of Clinical Pathways
Conference Coverage
Real-World Treatment Patterns in US Veterans With Nonmetastatic Castration–Resistant Prostate Cancer
06/03/2022

Marta Rybczynski

Marta Rybczynski
Despite the recent approval of several nmCRPC treatments that have demonstrated improved metastasis-free survival and quality of life, first-generation antiandrogens remain the predominant first-line treatment among these patients.
Despite the recent approval of several nmCRPC treatments that have demonstrated improved metastasis-free survival and quality of life, first-generation antiandrogens remain the predominant first-line treatment among these patients.
Despite the recent approval of...
06/03/2022
Journal of Clinical Pathways
Conference Coverage
Financial Impact of Switching From Abiraterone to Generic Therapeutics for Patients With Prostate Cancer in the Oncology Care Model
06/03/2022

Amber Denham

Amber Denham
Therapeutic interchange from brand name to generic abiraterone in The US Oncology Network generated significant savings for the Oncology Care Model, according to a study presented at the 2022 ASCO Annual Meeting.
Therapeutic interchange from brand name to generic abiraterone in The US Oncology Network generated significant savings for the Oncology Care Model, according to a study presented at the 2022 ASCO Annual Meeting.
Therapeutic interchange from...
06/03/2022
Journal of Clinical Pathways
Conference Coverage
Oncologist vs Urologist Treatment Decision-Making for Metastatic Castration–Sensitive Prostate Cancer in the United States
06/03/2022

Janelle Bradley

Janelle Bradley
Study findings presented at the 2022 ASCO Annual Meeting reveal oncologists’ and urologists’ reasons for underutilization of treatment intensification for patients with metastatic castration–sensitive prostate cancer.
Study findings presented at the 2022 ASCO Annual Meeting reveal oncologists’ and urologists’ reasons for underutilization of treatment intensification for patients with metastatic castration–sensitive prostate cancer.
Study findings presented at the...
06/03/2022
Journal of Clinical Pathways
Peter Martin, MD, Weill Cornell Medicine
Videos
Real-World Treatment Patterns and Outcomes Among Patients With MCL
08/20/2021
Peter Martin, MD, real-world treatment patterns and outcomes among 3455 patients with previously untreated MCL in the United States.
Peter Martin, MD, real-world treatment patterns and outcomes among 3455 patients with previously untreated MCL in the United States.
Peter Martin, MD, real-world...
08/20/2021
Journal of Clinical Pathways
Jinan Liu, MD, PhD
Videos
Real-World Maintenance Therapy Use in Newly Diagnosed Ovarian Cancer
07/24/2021
Jinan Liu, MD, discusses results from a real-world study exploring patterns and predictors of maintenance therapy use among patients with newly diagnosed ovarian cancer.
Jinan Liu, MD, discusses results from a real-world study exploring patterns and predictors of maintenance therapy use among patients with newly diagnosed ovarian cancer.
Jinan Liu, MD, discusses results...
07/24/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Perioperative Chemotherapy vs Adjuvant Chemoradiation for Gastric Cancer
07/20/2021
A recent study comparing perioperative chemotherapy with adjuvant chemoradiotherapy among patients with gastric cancer suggests that perioperative chemotherapy may be more cost-effective.
A recent study comparing perioperative chemotherapy with adjuvant chemoradiotherapy among patients with gastric cancer suggests that perioperative chemotherapy may be more cost-effective.
A recent study comparing...
07/20/2021
Journal of Clinical Pathways
Katrine Wallace, PhD, MS
Videos
Real-World Utilization of Second-Line Maintenance Therapy for Advanced Ovarian Cancer
07/19/2021
Katrine Wallace, PhD, MS, discusses study findings estimating the real-world utilization of second-line maintenance therapy for patients with advanced ovarian cancer in the United States.
Katrine Wallace, PhD, MS, discusses study findings estimating the real-world utilization of second-line maintenance therapy for patients with advanced ovarian cancer in the United States.
Katrine Wallace, PhD, MS,...
07/19/2021
Journal of Clinical Pathways
Videos
Bendamustine Plus Rituximab Safe, Effective for Treating MCL in Real-World Setting
07/15/2021
Rouslan Kotchetkov, MD, PhD, discusses results from a retrospective review exploring the efficacy and safety of bendamustine plus rituximab for the treatment of MCL in the real-world setting.
Rouslan Kotchetkov, MD, PhD, discusses results from a retrospective review exploring the efficacy and safety of bendamustine plus rituximab for the treatment of MCL in the real-world setting.
Rouslan Kotchetkov, MD, PhD,...
07/15/2021
Journal of Clinical Pathways
Conference Coverage
Real-World PFS Among Patients With Ovarian Cancer Receiving First-Line Maintenance Therapy vs Active Surveillance
07/14/2021
Though most patients with ovarian cancer do not receive first-line maintenance therapy, those who do may be more likely to experience improved PFS.
Though most patients with ovarian cancer do not receive first-line maintenance therapy, those who do may be more likely to experience improved PFS.
Though most patients with...
07/14/2021
Journal of Clinical Pathways
Conference Coverage
Budget Impact Analysis of Body Surface Area vs Flat-Fixed Rituximab Dosing for NHL and CLL
07/08/2021
Study findings suggest there may be economic benefit in replacing a proportion of flat-fixed rituximab/hyaluronidase human subcutaneous injection use with body surface area-based rituximab-abbs for patients with NHL and CLL from a US payer...
Study findings suggest there may be economic benefit in replacing a proportion of flat-fixed rituximab/hyaluronidase human subcutaneous injection use with body surface area-based rituximab-abbs for patients with NHL and CLL from a US payer...
Study findings suggest there may...
07/08/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Perioperative Chemotherapy vs Adjuvant Chemoradiotherapy for Gastric Cancer
07/07/2021
A recent study comparing perioperative chemotherapy and adjuvant chemoradiotherapy for the treatment of gastric cancer identified the more cost-effective treatment of the two.
A recent study comparing perioperative chemotherapy and adjuvant chemoradiotherapy for the treatment of gastric cancer identified the more cost-effective treatment of the two.
A recent study comparing...
07/07/2021
Journal of Clinical Pathways
Conference Coverage
Real-world Treatment Patterns and Outcomes Among Patients With MCL in the United States
07/02/2021
Findings from a real-world study show bendamustine plus rituximab was the most commonly used first-line treatment for MCL in the United States and that receipt of stem cell transplant was not common.
Findings from a real-world study show bendamustine plus rituximab was the most commonly used first-line treatment for MCL in the United States and that receipt of stem cell transplant was not common.
Findings from a real-world study...
07/02/2021
Journal of Clinical Pathways
Conference Coverage
Health Care Burden of Patients Hospitalized for Testicular Carcinoma
07/02/2021
Increasing costs of stay for patients hospitalized with testicular carcinoma are out of proportion with increases in length of stay, leading to significant financial toxicity for these patients.
Increasing costs of stay for patients hospitalized with testicular carcinoma are out of proportion with increases in length of stay, leading to significant financial toxicity for these patients.
Increasing costs of stay for...
07/02/2021
Journal of Clinical Pathways
Kishan Patel, MD, Yale School of Medicine
Videos
Atezolizumab Plus Bevacizumab Unlikely Cost-Effective for Advanced HCC
07/01/2021
Kishan Patel, MD, discusses results from a study evaluating the cost-effectiveness of atezolizumab plus bevacizumab for advanced HCC, concluding that it may be too costly under current pricing.
Kishan Patel, MD, discusses results from a study evaluating the cost-effectiveness of atezolizumab plus bevacizumab for advanced HCC, concluding that it may be too costly under current pricing.
Kishan Patel, MD, discusses...
07/01/2021
Journal of Clinical Pathways
Videos
Cost-Effectiveness of Adjuvant Osimertinib for EGFR-Mutant NSCLC
07/01/2021
Christopher Lemmon, MD, discusses results from a study on the cost-effectiveness of adjuvant osimertinib in resected EGFR mutant NSCLC patients, finding that it may have the potential to be cost-effective, given the right financial...
Christopher Lemmon, MD, discusses results from a study on the cost-effectiveness of adjuvant osimertinib in resected EGFR mutant NSCLC patients, finding that it may have the potential to be cost-effective, given the right financial...
Christopher Lemmon, MD,...
07/01/2021
Journal of Clinical Pathways
News
Real-World Practice Patterns for First-Line Treatment of Metastatic Breast Cancer
06/29/2021
Study results show substantial variation in treatment selection and costs for first-line treatment of patients with metastatic breast cancer in Washington State.
Study results show substantial variation in treatment selection and costs for first-line treatment of patients with metastatic breast cancer in Washington State.
Study results show substantial...
06/29/2021
Journal of Clinical Pathways
Conference Coverage
Real-world PSA Progression After Enzalutamide or Abiraterone for Metastatic CRPC
06/24/2021
A real-world study presented at the virtual 2021 ASCO Annual Meeting evaluated prostate-specific antigen pattern progression and its association with OS among patients with metastatic CRPC who were treated with enzalutamide or abiraterone.
A real-world study presented at the virtual 2021 ASCO Annual Meeting evaluated prostate-specific antigen pattern progression and its association with OS among patients with metastatic CRPC who were treated with enzalutamide or abiraterone.
A real-world study presented at...
06/24/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Two Testing Strategies for BRCA Mutations in Ovarian Cancer
06/23/2021
A study presented at the virtual 2021 ASCO Annual Meeting compared the cost-effectiveness of two testing strategies for patients with ovarian cancer.
A study presented at the virtual 2021 ASCO Annual Meeting compared the cost-effectiveness of two testing strategies for patients with ovarian cancer.
A study presented at the virtual...
06/23/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Patterns and Predictors of First-Line Maintenance Therapy Use in Ovarian Cancer
06/23/2021
First-line maintenance therapy use for ovarian cancer has increased over time, particularly among patients with biomarker guidance.
First-line maintenance therapy use for ovarian cancer has increased over time, particularly among patients with biomarker guidance.
First-line maintenance therapy...
06/23/2021
Journal of Clinical Pathways
Videos
Rucaparib vs Chemotherapy for Platinum-Sensitive Patients With Advanced Ovarian Cancer
06/23/2021
David O'Malley, MD, discusses results from a subgroup analysis of the ARIEL4 trial, comparing rucaparib vs chemotherapy among platinum-sensitive patients with ovarian cancer.
David O'Malley, MD, discusses results from a subgroup analysis of the ARIEL4 trial, comparing rucaparib vs chemotherapy among platinum-sensitive patients with ovarian cancer.
David O'Malley, MD, discusses...
06/23/2021
Journal of Clinical Pathways
Conference Coverage
Physician- and Patient-Reported Outcomes Among Five Radiotherapy Methods for Prostate Cancer
06/21/2021
A recent study comparing radiotherapy methods for prostate cancer suggests that physician-reported toxicities may be lower for patients treated with high-dose-rate brachytherapy, and patient-reported outcomes may be worse for those treated...
A recent study comparing radiotherapy methods for prostate cancer suggests that physician-reported toxicities may be lower for patients treated with high-dose-rate brachytherapy, and patient-reported outcomes may be worse for those treated...
A recent study comparing...
06/21/2021
Journal of Clinical Pathways
Conference Coverage
Real-World First-Line Treatment Patterns in Commercially Insured Patients With CSPC
06/17/2021
A majority of commercially insured and Medicare patients with metastatic castration-sensitive prostate cancer may not be receiving optimal life-prolonging therapies.
A majority of commercially insured and Medicare patients with metastatic castration-sensitive prostate cancer may not be receiving optimal life-prolonging therapies.
A majority of commercially...
06/17/2021
Journal of Clinical Pathways
Conference Coverage
An International Analysis of Treatments and Outcomes Among Patients with Epithelial Ovarian Cancer
06/17/2021
A new study suggests variation in patient populations between sites, and differences in treatments and outcomes across international networks of epithelial ovarian cancer treatment centers.
A new study suggests variation in patient populations between sites, and differences in treatments and outcomes across international networks of epithelial ovarian cancer treatment centers.
A new study suggests variation...
06/17/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer
06/14/2021
More than half of patients with metastatic castration-sensitive prostate cancer did not receive first-line treatment regimens associated with improved survival compared with ADT alone in the community practice setting.
More than half of patients with metastatic castration-sensitive prostate cancer did not receive first-line treatment regimens associated with improved survival compared with ADT alone in the community practice setting.
More than half of patients with...
06/14/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Utilization of Advanced Therapies for Metastatic Castration-Sensitive Prostate Cancer
06/14/2021
In a large representative sample of US patients with metastatic castration-sensitive prostate cancer, less than one-third of patients received advanced therapies by 2018, and this was especially less frequent in Black patients.
In a large representative sample of US patients with metastatic castration-sensitive prostate cancer, less than one-third of patients received advanced therapies by 2018, and this was especially less frequent in Black patients.
In a large representative sample...
06/14/2021
Journal of Clinical Pathways
Videos
Cost-Effectiveness of Adjunctive Osimertinib for EGFR-Positive NSCLC
06/10/2021
Briana Choi, PharmD, discusses results from a study evaluating the cost-effectiveness of adjunctive maintenance therapy with osimertinib in resected EGFR-positive NSCLC, finding that it varies across stages of disease.
Briana Choi, PharmD, discusses results from a study evaluating the cost-effectiveness of adjunctive maintenance therapy with osimertinib in resected EGFR-positive NSCLC, finding that it varies across stages of disease.
Briana Choi, PharmD, discusses...
06/10/2021
Journal of Clinical Pathways
Conference Coverage
Real-World PARP Inhibitor Toxicities in Ovarian Cancer Consistent With Clinical Trials
06/07/2021
In routine clinical practice, toxicities from PARP inhibitor therapy in patients with relapsed ovarian cancer are low grade and occur early in treatment, consistent with phase 3 trials clinical trials.
In routine clinical practice, toxicities from PARP inhibitor therapy in patients with relapsed ovarian cancer are low grade and occur early in treatment, consistent with phase 3 trials clinical trials.
In routine clinical practice,...
06/07/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Utilization of Second-Line Maintenance Therapy for Patients With Ovarian Cancer
06/07/2021
Fewer than half of eligible patients with advanced ovarian cancer receive second-line maintenance therapy, according to results from a real-world analysis.
Fewer than half of eligible patients with advanced ovarian cancer receive second-line maintenance therapy, according to results from a real-world analysis.
Fewer than half of eligible...
06/07/2021
Journal of Clinical Pathways
Conference Coverage
Treatment Patterns Following First-Line Therapy for HER2-Positive Metastatic Breast Cancer
06/07/2021
A study exploring practice patterns in HER2-positive breast cancer in the United States found that the most common second-line treatment following first-line pertuzumab plus trastuzumab were T-DM1-based regimens.
A study exploring practice patterns in HER2-positive breast cancer in the United States found that the most common second-line treatment following first-line pertuzumab plus trastuzumab were T-DM1-based regimens.
A study exploring practice...
06/07/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Outcomes of Patients Receiving Alpelisib for PIK3CA-Mutated Breast Cancer
06/07/2021
Patients with breast cancer and PIK3CA mutations who receive alpelisib plus fulvestrant have longer real-world PFS compared with those who receive fulvestrant alone.
Patients with breast cancer and PIK3CA mutations who receive alpelisib plus fulvestrant have longer real-world PFS compared with those who receive fulvestrant alone.
Patients with breast cancer and...
06/07/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Subcutaneous Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for Early Breast Cancer
06/07/2021
Neoadjuvant pertuzumab, trastuzumab, and hyaluronidase-zzxf plus chemotherapy is expected to be cost-effective vs neoadjuvant pertuzumab and trastuzumab plus chemotherapy for patients with high-risk HER2-positive early breast cancer.
Neoadjuvant pertuzumab, trastuzumab, and hyaluronidase-zzxf plus chemotherapy is expected to be cost-effective vs neoadjuvant pertuzumab and trastuzumab plus chemotherapy for patients with high-risk HER2-positive early breast cancer.
Neoadjuvant pertuzumab,...
06/07/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Adjuvant Osimertinib vs Placebo in NSCLC
06/02/2021
Study findings suggest adjuvant osimertinib is more cost-effective than placebo if one is willing to pay $317,119 more per QALY gained.
Study findings suggest adjuvant osimertinib is more cost-effective than placebo if one is willing to pay $317,119 more per QALY gained.
Study findings suggest adjuvant...
06/02/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Temozolomide Use in Patients with Glioblastoma
06/02/2021
Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.
Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.
Study findings support...
06/02/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement